Failure to confirm major objective antit
โ
Paul N. M. Cheng; Leonard B. Saltz
๐
Article
๐
1999
๐
John Wiley and Sons
๐
English
โ 60 KB
๐ 1 views
## BACKGROUND. The combination regimen of streptozocin plus doxorubicin is the current standard chemotherapeutic treatment of symptomatic or progressing metastatic islet cell carcinoma. This regimen previously has been reported to have a major objective response rate of 69% in a randomized coopera